/ALDEI.PA

ALDEI.PA Stock - Deinove S.A.

Q: What is the analyst price target for ALDEI.PA?

Analyst price target information is not currently available for ALDEI.PA.

Q: What is ALDEI.PA's market cap?

Market capitalization information is not currently available for ALDEI.PA.

Healthcare|Biotechnology|PAR

$0.03+0.00%

+$0.00 (+0.00%) • Jan 10

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.03

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ALDEI.PA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.79

52W High$0.44

52W Low$0.01

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	$367,000	$323,000	$163,000	$39,000	$73,000
Gross Profit	$-3,318,000	$-3,594,000	$-7,009,000	$-4,843,000	$-4,466,000
Gross Margin	-904.1%	-1112.7%	-4300.0%	-12417.9%	-6117.8%
Operating Income	$-7,331,000	$-8,125,000	$-12,201,000	$-10,467,000	$-9,681,000
Net Income	$-6,991,000	$-6,792,000	$-9,801,000	$-8,459,000	$-7,256,000
Net Margin	-1904.9%	-2102.8%	-6012.9%	-21689.7%	-9939.7%
EPS	$-0.24	$-0.28	$-0.59	$-0.61	$-0.68

Company Overview

DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME Oléoactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioMérieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Oléos-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.

Visit Website